nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—PDGFRA—brain cancer	0.365	1	CbGaD
Dasatinib—CYP1B1—Procarbazine—brain cancer	0.146	0.592	CbGbCtD
Dasatinib—CYP1A2—Carmustine—brain cancer	0.0198	0.0804	CbGbCtD
Dasatinib—ABCG2—Carboplatin—brain cancer	0.0169	0.0688	CbGbCtD
Dasatinib—CYP3A4—Temozolomide—brain cancer	0.0149	0.0608	CbGbCtD
Dasatinib—ABCG2—Etoposide—brain cancer	0.0142	0.0578	CbGbCtD
Dasatinib—CYP3A4—Lomustine—brain cancer	0.0127	0.0517	CbGbCtD
Dasatinib—CYP3A5—Etoposide—brain cancer	0.00787	0.032	CbGbCtD
Dasatinib—CYP1A2—Etoposide—brain cancer	0.00586	0.0238	CbGbCtD
Dasatinib—ABCB1—Etoposide—brain cancer	0.00512	0.0208	CbGbCtD
Dasatinib—CYP3A4—Etoposide—brain cancer	0.00307	0.0125	CbGbCtD
Dasatinib—ERBB3—Podofilox—Etoposide—brain cancer	0.00167	1	CbGdCrCtD
Dasatinib—EPHB4—pituitary gland—brain cancer	0.000234	0.00224	CbGeAlD
Dasatinib—ERBB3—midbrain—brain cancer	0.000234	0.00223	CbGeAlD
Dasatinib—SIK1—spinal cord—brain cancer	0.000233	0.00222	CbGeAlD
Dasatinib—STK35—endocrine gland—brain cancer	0.000233	0.00222	CbGeAlD
Dasatinib—JAK2—pituitary gland—brain cancer	0.000233	0.00222	CbGeAlD
Dasatinib—CSK—endocrine gland—brain cancer	0.000231	0.00221	CbGeAlD
Dasatinib—STK35—head—brain cancer	0.00023	0.00219	CbGeAlD
Dasatinib—EPHA2—pituitary gland—brain cancer	0.00023	0.00219	CbGeAlD
Dasatinib—MAP3K3—gonad—brain cancer	0.00023	0.00219	CbGeAlD
Dasatinib—MAP4K5—gonad—brain cancer	0.00023	0.00219	CbGeAlD
Dasatinib—FYN—pituitary gland—brain cancer	0.000229	0.00219	CbGeAlD
Dasatinib—CSK—head—brain cancer	0.000228	0.00218	CbGeAlD
Dasatinib—HCK—endocrine gland—brain cancer	0.000228	0.00218	CbGeAlD
Dasatinib—ERBB3—spinal cord—brain cancer	0.000228	0.00218	CbGeAlD
Dasatinib—TESK1—central nervous system—brain cancer	0.000228	0.00217	CbGeAlD
Dasatinib—EPHB4—medulla oblongata—brain cancer	0.000226	0.00216	CbGeAlD
Dasatinib—EPHA3—brain—brain cancer	0.000226	0.00216	CbGeAlD
Dasatinib—HCK—head—brain cancer	0.000225	0.00215	CbGeAlD
Dasatinib—MAP2K5—telencephalon—brain cancer	0.000225	0.00215	CbGeAlD
Dasatinib—KIT—brainstem—brain cancer	0.000225	0.00214	CbGeAlD
Dasatinib—JAK2—medulla oblongata—brain cancer	0.000224	0.00214	CbGeAlD
Dasatinib—MAP4K5—pituitary gland—brain cancer	0.000224	0.00214	CbGeAlD
Dasatinib—MAP3K3—pituitary gland—brain cancer	0.000224	0.00214	CbGeAlD
Dasatinib—STK36—central nervous system—brain cancer	0.000224	0.00214	CbGeAlD
Dasatinib—EPHB3—central nervous system—brain cancer	0.000224	0.00214	CbGeAlD
Dasatinib—TESK1—cerebellum—brain cancer	0.000222	0.00212	CbGeAlD
Dasatinib—FYN—medulla oblongata—brain cancer	0.000221	0.00211	CbGeAlD
Dasatinib—SIK3—brain—brain cancer	0.00022	0.0021	CbGeAlD
Dasatinib—CSF1R—telencephalon—brain cancer	0.00022	0.0021	CbGeAlD
Dasatinib—EPHB3—cerebellum—brain cancer	0.000219	0.00209	CbGeAlD
Dasatinib—STK36—cerebellum—brain cancer	0.000219	0.00209	CbGeAlD
Dasatinib—LIMK2—central nervous system—brain cancer	0.000216	0.00207	CbGeAlD
Dasatinib—MAP3K3—medulla oblongata—brain cancer	0.000216	0.00206	CbGeAlD
Dasatinib—MAP4K5—medulla oblongata—brain cancer	0.000216	0.00206	CbGeAlD
Dasatinib—RIPK2—endocrine gland—brain cancer	0.000215	0.00205	CbGeAlD
Dasatinib—EPHB6—pituitary gland—brain cancer	0.000214	0.00204	CbGeAlD
Dasatinib—MAPK14—spinal cord—brain cancer	0.000213	0.00203	CbGeAlD
Dasatinib—YES1—gonad—brain cancer	0.000212	0.00203	CbGeAlD
Dasatinib—RIPK2—head—brain cancer	0.000212	0.00202	CbGeAlD
Dasatinib—LIMK2—cerebellum—brain cancer	0.000212	0.00202	CbGeAlD
Dasatinib—STK35—central nervous system—brain cancer	0.00021	0.002	CbGeAlD
Dasatinib—SIK1—endocrine gland—brain cancer	0.00021	0.002	CbGeAlD
Dasatinib—CSK—central nervous system—brain cancer	0.000208	0.00199	CbGeAlD
Dasatinib—PDGFRA—gonad—brain cancer	0.000208	0.00199	CbGeAlD
Dasatinib—EPHA4—endocrine gland—brain cancer	0.000208	0.00198	CbGeAlD
Dasatinib—SIK1—head—brain cancer	0.000207	0.00198	CbGeAlD
Dasatinib—YES1—pituitary gland—brain cancer	0.000207	0.00198	CbGeAlD
Dasatinib—EPHB6—medulla oblongata—brain cancer	0.000207	0.00197	CbGeAlD
Dasatinib—EPHB4—midbrain—brain cancer	0.000207	0.00197	CbGeAlD
Dasatinib—HCK—central nervous system—brain cancer	0.000206	0.00196	CbGeAlD
Dasatinib—ERBB3—endocrine gland—brain cancer	0.000205	0.00196	CbGeAlD
Dasatinib—STK35—cerebellum—brain cancer	0.000205	0.00196	CbGeAlD
Dasatinib—EPHA4—head—brain cancer	0.000205	0.00196	CbGeAlD
Dasatinib—ZAK—brain—brain cancer	0.000204	0.00195	CbGeAlD
Dasatinib—SRC—gonad—brain cancer	0.000204	0.00195	CbGeAlD
Dasatinib—CSK—cerebellum—brain cancer	0.000204	0.00194	CbGeAlD
Dasatinib—MAP3K2—endocrine gland—brain cancer	0.000204	0.00194	CbGeAlD
Dasatinib—ERBB3—head—brain cancer	0.000203	0.00194	CbGeAlD
Dasatinib—FYN—midbrain—brain cancer	0.000202	0.00193	CbGeAlD
Dasatinib—EPHB4—spinal cord—brain cancer	0.000201	0.00192	CbGeAlD
Dasatinib—MAP3K2—head—brain cancer	0.000201	0.00192	CbGeAlD
Dasatinib—JAK2—spinal cord—brain cancer	0.0002	0.00191	CbGeAlD
Dasatinib—EPHA5—brain—brain cancer	0.0002	0.00191	CbGeAlD
Dasatinib—ABL2—cerebellum—brain cancer	0.0002	0.00191	CbGeAlD
Dasatinib—YES1—medulla oblongata—brain cancer	0.0002	0.00191	CbGeAlD
Dasatinib—KIT—telencephalon—brain cancer	0.000199	0.0019	CbGeAlD
Dasatinib—LYN—brain—brain cancer	0.000199	0.0019	CbGeAlD
Dasatinib—MAP3K3—midbrain—brain cancer	0.000198	0.00189	CbGeAlD
Dasatinib—MAP4K5—midbrain—brain cancer	0.000198	0.00189	CbGeAlD
Dasatinib—FYN—spinal cord—brain cancer	0.000197	0.00188	CbGeAlD
Dasatinib—MAP3K19—brain—brain cancer	0.000196	0.00187	CbGeAlD
Dasatinib—BMPR1B—brain—brain cancer	0.000196	0.00187	CbGeAlD
Dasatinib—ABL1—brainstem—brain cancer	0.000196	0.00187	CbGeAlD
Dasatinib—BTK—brain—brain cancer	0.000195	0.00186	CbGeAlD
Dasatinib—PDGFRB—telencephalon—brain cancer	0.000195	0.00186	CbGeAlD
Dasatinib—MAP3K3—spinal cord—brain cancer	0.000193	0.00184	CbGeAlD
Dasatinib—MAP4K5—spinal cord—brain cancer	0.000193	0.00184	CbGeAlD
Dasatinib—TNK2—brain—brain cancer	0.000192	0.00183	CbGeAlD
Dasatinib—MAPK14—endocrine gland—brain cancer	0.000191	0.00183	CbGeAlD
Dasatinib—FGR—endocrine gland—brain cancer	0.000191	0.00182	CbGeAlD
Dasatinib—RIPK2—cerebellum—brain cancer	0.000189	0.00181	CbGeAlD
Dasatinib—SIK1—central nervous system—brain cancer	0.000189	0.0018	CbGeAlD
Dasatinib—MAPK14—head—brain cancer	0.000189	0.0018	CbGeAlD
Dasatinib—EPHB6—midbrain—brain cancer	0.000189	0.0018	CbGeAlD
Dasatinib—FGR—head—brain cancer	0.000188	0.0018	CbGeAlD
Dasatinib—Stomatitis—Carmustine—brain cancer	0.000187	0.00152	CcSEcCtD
Dasatinib—EPHA4—central nervous system—brain cancer	0.000187	0.00179	CbGeAlD
Dasatinib—Pneumonia—Temozolomide—brain cancer	0.000187	0.00152	CcSEcCtD
Dasatinib—Anorexia—Procarbazine—brain cancer	0.000187	0.00152	CcSEcCtD
Dasatinib—Erythema—Hydroxyurea—brain cancer	0.000186	0.00151	CcSEcCtD
Dasatinib—Infestation—Temozolomide—brain cancer	0.000186	0.00151	CcSEcCtD
Dasatinib—Infestation NOS—Temozolomide—brain cancer	0.000186	0.00151	CcSEcCtD
Dasatinib—ERBB3—central nervous system—brain cancer	0.000185	0.00177	CbGeAlD
Dasatinib—SIK1—cerebellum—brain cancer	0.000185	0.00176	CbGeAlD
Dasatinib—EPHB6—spinal cord—brain cancer	0.000184	0.00176	CbGeAlD
Dasatinib—FMO3—endocrine gland—brain cancer	0.000184	0.00176	CbGeAlD
Dasatinib—MAP3K2—central nervous system—brain cancer	0.000183	0.00175	CbGeAlD
Dasatinib—Nausea—Lomustine—brain cancer	0.000183	0.00149	CcSEcCtD
Dasatinib—CSF1R—gonad—brain cancer	0.000183	0.00175	CbGeAlD
Dasatinib—MAP2K5—pituitary gland—brain cancer	0.000183	0.00175	CbGeAlD
Dasatinib—Hypotension—Procarbazine—brain cancer	0.000183	0.00149	CcSEcCtD
Dasatinib—EPHA4—cerebellum—brain cancer	0.000183	0.00174	CbGeAlD
Dasatinib—YES1—midbrain—brain cancer	0.000183	0.00174	CbGeAlD
Dasatinib—Neuropathy peripheral—Temozolomide—brain cancer	0.000182	0.00148	CcSEcCtD
Dasatinib—FMO3—head—brain cancer	0.000182	0.00173	CbGeAlD
Dasatinib—EPHB4—endocrine gland—brain cancer	0.000181	0.00173	CbGeAlD
Dasatinib—ERBB3—cerebellum—brain cancer	0.000181	0.00173	CbGeAlD
Dasatinib—Stomatitis—Temozolomide—brain cancer	0.000181	0.00147	CcSEcCtD
Dasatinib—TESK1—brain—brain cancer	0.000181	0.00172	CbGeAlD
Dasatinib—JAK2—endocrine gland—brain cancer	0.00018	0.00172	CbGeAlD
Dasatinib—MAP3K2—cerebellum—brain cancer	0.000179	0.00171	CbGeAlD
Dasatinib—CSF1R—pituitary gland—brain cancer	0.000179	0.00171	CbGeAlD
Dasatinib—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000178	0.00145	CcSEcCtD
Dasatinib—YES1—spinal cord—brain cancer	0.000178	0.0017	CbGeAlD
Dasatinib—EPHA2—endocrine gland—brain cancer	0.000178	0.0017	CbGeAlD
Dasatinib—JAK2—head—brain cancer	0.000178	0.0017	CbGeAlD
Dasatinib—STK36—brain—brain cancer	0.000178	0.0017	CbGeAlD
Dasatinib—EPHB3—brain—brain cancer	0.000178	0.0017	CbGeAlD
Dasatinib—FYN—endocrine gland—brain cancer	0.000178	0.0017	CbGeAlD
Dasatinib—Insomnia—Procarbazine—brain cancer	0.000177	0.00144	CcSEcCtD
Dasatinib—MAP2K5—medulla oblongata—brain cancer	0.000177	0.00169	CbGeAlD
Dasatinib—EPHA2—head—brain cancer	0.000176	0.00168	CbGeAlD
Dasatinib—Hepatobiliary disease—Temozolomide—brain cancer	0.000176	0.00143	CcSEcCtD
Dasatinib—FYN—head—brain cancer	0.000175	0.00167	CbGeAlD
Dasatinib—PDGFRA—spinal cord—brain cancer	0.000175	0.00167	CbGeAlD
Dasatinib—Somnolence—Procarbazine—brain cancer	0.000174	0.00141	CcSEcCtD
Dasatinib—MAP4K5—endocrine gland—brain cancer	0.000174	0.00166	CbGeAlD
Dasatinib—MAP3K3—endocrine gland—brain cancer	0.000174	0.00166	CbGeAlD
Dasatinib—ABL1—telencephalon—brain cancer	0.000174	0.00166	CbGeAlD
Dasatinib—Haemoglobin—Carmustine—brain cancer	0.000173	0.00141	CcSEcCtD
Dasatinib—CSF1R—medulla oblongata—brain cancer	0.000172	0.00165	CbGeAlD
Dasatinib—Haemorrhage—Carmustine—brain cancer	0.000172	0.0014	CcSEcCtD
Dasatinib—MAPK14—central nervous system—brain cancer	0.000172	0.00165	CbGeAlD
Dasatinib—Ill-defined disorder—Hydroxyurea—brain cancer	0.000172	0.0014	CcSEcCtD
Dasatinib—LIMK2—brain—brain cancer	0.000172	0.00164	CbGeAlD
Dasatinib—FGR—central nervous system—brain cancer	0.000172	0.00164	CbGeAlD
Dasatinib—Anaemia—Hydroxyurea—brain cancer	0.000172	0.00139	CcSEcCtD
Dasatinib—MAP4K5—head—brain cancer	0.000171	0.00164	CbGeAlD
Dasatinib—MAP3K3—head—brain cancer	0.000171	0.00164	CbGeAlD
Dasatinib—SRC—spinal cord—brain cancer	0.000171	0.00164	CbGeAlD
Dasatinib—Decreased appetite—Procarbazine—brain cancer	0.00017	0.00138	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Etoposide—brain cancer	0.00017	0.00138	CcSEcCtD
Dasatinib—Oedema peripheral—Carmustine—brain cancer	0.00017	0.00138	CcSEcCtD
Dasatinib—Connective tissue disorder—Carmustine—brain cancer	0.000169	0.00138	CcSEcCtD
Dasatinib—Fatigue—Procarbazine—brain cancer	0.000169	0.00137	CcSEcCtD
Dasatinib—MAPK14—cerebellum—brain cancer	0.000169	0.00161	CbGeAlD
Dasatinib—Haemoglobin—Temozolomide—brain cancer	0.000167	0.00136	CcSEcCtD
Dasatinib—Malaise—Hydroxyurea—brain cancer	0.000167	0.00136	CcSEcCtD
Dasatinib—Pain—Procarbazine—brain cancer	0.000167	0.00136	CcSEcCtD
Dasatinib—Constipation—Procarbazine—brain cancer	0.000167	0.00136	CcSEcCtD
Dasatinib—Hepatitis—Temozolomide—brain cancer	0.000167	0.00135	CcSEcCtD
Dasatinib—Haemorrhage—Temozolomide—brain cancer	0.000167	0.00135	CcSEcCtD
Dasatinib—Dysphagia—Etoposide—brain cancer	0.000167	0.00135	CcSEcCtD
Dasatinib—STK35—brain—brain cancer	0.000167	0.00159	CbGeAlD
Dasatinib—KIT—gonad—brain cancer	0.000166	0.00159	CbGeAlD
Dasatinib—Visual impairment—Carmustine—brain cancer	0.000166	0.00135	CcSEcCtD
Dasatinib—FMO3—central nervous system—brain cancer	0.000166	0.00158	CbGeAlD
Dasatinib—CSK—brain—brain cancer	0.000165	0.00158	CbGeAlD
Dasatinib—Urinary tract disorder—Temozolomide—brain cancer	0.000165	0.00134	CcSEcCtD
Dasatinib—Oedema peripheral—Temozolomide—brain cancer	0.000164	0.00133	CcSEcCtD
Dasatinib—Bronchospasm—Etoposide—brain cancer	0.000164	0.00133	CcSEcCtD
Dasatinib—EPHB6—head—brain cancer	0.000164	0.00156	CbGeAlD
Dasatinib—Connective tissue disorder—Temozolomide—brain cancer	0.000164	0.00133	CcSEcCtD
Dasatinib—Urethral disorder—Temozolomide—brain cancer	0.000163	0.00133	CcSEcCtD
Dasatinib—HCK—brain—brain cancer	0.000163	0.00156	CbGeAlD
Dasatinib—PDGFRB—gonad—brain cancer	0.000162	0.00155	CbGeAlD
Dasatinib—ABL2—brain—brain cancer	0.000162	0.00155	CbGeAlD
Dasatinib—JAK2—central nervous system—brain cancer	0.000162	0.00155	CbGeAlD
Dasatinib—KIT—pituitary gland—brain cancer	0.000162	0.00155	CbGeAlD
Dasatinib—MAP2K5—midbrain—brain cancer	0.000162	0.00154	CbGeAlD
Dasatinib—Feeling abnormal—Procarbazine—brain cancer	0.000161	0.00131	CcSEcCtD
Dasatinib—Eye disorder—Carmustine—brain cancer	0.000161	0.00131	CcSEcCtD
Dasatinib—Convulsion—Hydroxyurea—brain cancer	0.000161	0.00131	CcSEcCtD
Dasatinib—Visual impairment—Temozolomide—brain cancer	0.000161	0.0013	CcSEcCtD
Dasatinib—EPHA2—central nervous system—brain cancer	0.00016	0.00153	CbGeAlD
Dasatinib—YES1—endocrine gland—brain cancer	0.00016	0.00153	CbGeAlD
Dasatinib—Gastrointestinal pain—Procarbazine—brain cancer	0.00016	0.0013	CcSEcCtD
Dasatinib—FYN—central nervous system—brain cancer	0.00016	0.00153	CbGeAlD
Dasatinib—Flushing—Carmustine—brain cancer	0.00016	0.0013	CcSEcCtD
Dasatinib—EPHB4—cerebellum—brain cancer	0.00016	0.00153	CbGeAlD
Dasatinib—JAK2—cerebellum—brain cancer	0.000159	0.00151	CbGeAlD
Dasatinib—PDGFRB—pituitary gland—brain cancer	0.000159	0.00151	CbGeAlD
Dasatinib—YES1—head—brain cancer	0.000158	0.00151	CbGeAlD
Dasatinib—Pancytopenia—Etoposide—brain cancer	0.000158	0.00128	CcSEcCtD
Dasatinib—CSF1R—midbrain—brain cancer	0.000158	0.0015	CbGeAlD
Dasatinib—MAP2K5—spinal cord—brain cancer	0.000158	0.0015	CbGeAlD
Dasatinib—Erythema multiforme—Temozolomide—brain cancer	0.000158	0.00128	CcSEcCtD
Dasatinib—PDGFRA—endocrine gland—brain cancer	0.000157	0.0015	CbGeAlD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000157	0.00127	CcSEcCtD
Dasatinib—KIT—medulla oblongata—brain cancer	0.000157	0.0015	CbGeAlD
Dasatinib—FYN—cerebellum—brain cancer	0.000156	0.00149	CbGeAlD
Dasatinib—MAP3K3—central nervous system—brain cancer	0.000156	0.00149	CbGeAlD
Dasatinib—MAP4K5—central nervous system—brain cancer	0.000156	0.00149	CbGeAlD
Dasatinib—Discomfort—Hydroxyurea—brain cancer	0.000156	0.00127	CcSEcCtD
Dasatinib—Neutropenia—Etoposide—brain cancer	0.000156	0.00126	CcSEcCtD
Dasatinib—Eye disorder—Temozolomide—brain cancer	0.000156	0.00126	CcSEcCtD
Dasatinib—Urticaria—Procarbazine—brain cancer	0.000156	0.00126	CcSEcCtD
Dasatinib—Tinnitus—Temozolomide—brain cancer	0.000155	0.00126	CcSEcCtD
Dasatinib—PDGFRA—head—brain cancer	0.000155	0.00148	CbGeAlD
Dasatinib—Abdominal pain—Procarbazine—brain cancer	0.000155	0.00126	CcSEcCtD
Dasatinib—Body temperature increased—Procarbazine—brain cancer	0.000155	0.00126	CcSEcCtD
Dasatinib—Cardiac disorder—Temozolomide—brain cancer	0.000155	0.00126	CcSEcCtD
Dasatinib—Flushing—Temozolomide—brain cancer	0.000155	0.00126	CcSEcCtD
Dasatinib—SRC—endocrine gland—brain cancer	0.000154	0.00147	CbGeAlD
Dasatinib—Arrhythmia—Carmustine—brain cancer	0.000154	0.00125	CcSEcCtD
Dasatinib—CSF1R—spinal cord—brain cancer	0.000154	0.00147	CbGeAlD
Dasatinib—RIPK2—brain—brain cancer	0.000154	0.00147	CbGeAlD
Dasatinib—PDGFRB—medulla oblongata—brain cancer	0.000153	0.00146	CbGeAlD
Dasatinib—MAP3K3—cerebellum—brain cancer	0.000153	0.00146	CbGeAlD
Dasatinib—MAP4K5—cerebellum—brain cancer	0.000153	0.00146	CbGeAlD
Dasatinib—Alopecia—Carmustine—brain cancer	0.000152	0.00124	CcSEcCtD
Dasatinib—SRC—head—brain cancer	0.000152	0.00145	CbGeAlD
Dasatinib—Oedema—Hydroxyurea—brain cancer	0.000152	0.00123	CcSEcCtD
Dasatinib—Angiopathy—Temozolomide—brain cancer	0.000151	0.00123	CcSEcCtD
Dasatinib—Mental disorder—Carmustine—brain cancer	0.000151	0.00123	CcSEcCtD
Dasatinib—Infection—Hydroxyurea—brain cancer	0.000151	0.00122	CcSEcCtD
Dasatinib—Immune system disorder—Temozolomide—brain cancer	0.000151	0.00122	CcSEcCtD
Dasatinib—Mediastinal disorder—Temozolomide—brain cancer	0.00015	0.00122	CcSEcCtD
Dasatinib—Malnutrition—Carmustine—brain cancer	0.00015	0.00122	CcSEcCtD
Dasatinib—Erythema—Carmustine—brain cancer	0.00015	0.00122	CcSEcCtD
Dasatinib—SIK1—brain—brain cancer	0.00015	0.00143	CbGeAlD
Dasatinib—Chills—Temozolomide—brain cancer	0.00015	0.00121	CcSEcCtD
Dasatinib—EPHB6—central nervous system—brain cancer	0.000149	0.00143	CbGeAlD
Dasatinib—Pneumonia—Etoposide—brain cancer	0.000149	0.00121	CcSEcCtD
Dasatinib—Nervous system disorder—Hydroxyurea—brain cancer	0.000149	0.00121	CcSEcCtD
Dasatinib—Infestation—Etoposide—brain cancer	0.000149	0.00121	CcSEcCtD
Dasatinib—Infestation NOS—Etoposide—brain cancer	0.000149	0.00121	CcSEcCtD
Dasatinib—EPHA4—brain—brain cancer	0.000148	0.00142	CbGeAlD
Dasatinib—Thrombocytopenia—Hydroxyurea—brain cancer	0.000148	0.0012	CcSEcCtD
Dasatinib—Alopecia—Temozolomide—brain cancer	0.000147	0.0012	CcSEcCtD
Dasatinib—Skin disorder—Hydroxyurea—brain cancer	0.000147	0.0012	CcSEcCtD
Dasatinib—ERBB3—brain—brain cancer	0.000147	0.0014	CbGeAlD
Dasatinib—CYP1B1—telencephalon—brain cancer	0.000147	0.0014	CbGeAlD
Dasatinib—Acute coronary syndrome—Etoposide—brain cancer	0.000146	0.00119	CcSEcCtD
Dasatinib—EPHB6—cerebellum—brain cancer	0.000146	0.00139	CbGeAlD
Dasatinib—Renal failure—Etoposide—brain cancer	0.000146	0.00119	CcSEcCtD
Dasatinib—Mental disorder—Temozolomide—brain cancer	0.000146	0.00119	CcSEcCtD
Dasatinib—Neuropathy peripheral—Etoposide—brain cancer	0.000146	0.00118	CcSEcCtD
Dasatinib—Myocardial infarction—Etoposide—brain cancer	0.000146	0.00118	CcSEcCtD
Dasatinib—MAP3K2—brain—brain cancer	0.000146	0.00139	CbGeAlD
Dasatinib—Erythema—Temozolomide—brain cancer	0.000145	0.00118	CcSEcCtD
Dasatinib—Malnutrition—Temozolomide—brain cancer	0.000145	0.00118	CcSEcCtD
Dasatinib—ABL1—gonad—brain cancer	0.000145	0.00138	CbGeAlD
Dasatinib—Stomatitis—Etoposide—brain cancer	0.000145	0.00118	CcSEcCtD
Dasatinib—YES1—central nervous system—brain cancer	0.000144	0.00138	CbGeAlD
Dasatinib—Anorexia—Hydroxyurea—brain cancer	0.000144	0.00117	CcSEcCtD
Dasatinib—Hypersensitivity—Procarbazine—brain cancer	0.000144	0.00117	CcSEcCtD
Dasatinib—KIT—midbrain—brain cancer	0.000143	0.00137	CbGeAlD
Dasatinib—Dysgeusia—Temozolomide—brain cancer	0.000142	0.00115	CcSEcCtD
Dasatinib—MAP2K5—endocrine gland—brain cancer	0.000142	0.00135	CbGeAlD
Dasatinib—PDGFRA—central nervous system—brain cancer	0.000142	0.00135	CbGeAlD
Dasatinib—Vision blurred—Carmustine—brain cancer	0.000141	0.00115	CcSEcCtD
Dasatinib—ABL1—pituitary gland—brain cancer	0.000141	0.00135	CbGeAlD
Dasatinib—YES1—cerebellum—brain cancer	0.000141	0.00135	CbGeAlD
Dasatinib—Tremor—Carmustine—brain cancer	0.000141	0.00114	CcSEcCtD
Dasatinib—Asthenia—Procarbazine—brain cancer	0.000141	0.00114	CcSEcCtD
Dasatinib—Hepatobiliary disease—Etoposide—brain cancer	0.00014	0.00114	CcSEcCtD
Dasatinib—MAP2K5—head—brain cancer	0.00014	0.00134	CbGeAlD
Dasatinib—PDGFRB—midbrain—brain cancer	0.00014	0.00133	CbGeAlD
Dasatinib—KIT—spinal cord—brain cancer	0.00014	0.00133	CbGeAlD
Dasatinib—SRC—central nervous system—brain cancer	0.000139	0.00133	CbGeAlD
Dasatinib—Anaemia—Carmustine—brain cancer	0.000139	0.00113	CcSEcCtD
Dasatinib—Pruritus—Procarbazine—brain cancer	0.000139	0.00112	CcSEcCtD
Dasatinib—PDGFRA—cerebellum—brain cancer	0.000139	0.00132	CbGeAlD
Dasatinib—CSF1R—endocrine gland—brain cancer	0.000138	0.00132	CbGeAlD
Dasatinib—MAPK14—brain—brain cancer	0.000137	0.00131	CbGeAlD
Dasatinib—Vision blurred—Temozolomide—brain cancer	0.000137	0.00111	CcSEcCtD
Dasatinib—CSF1R—head—brain cancer	0.000137	0.0013	CbGeAlD
Dasatinib—PDGFRB—spinal cord—brain cancer	0.000136	0.0013	CbGeAlD
Dasatinib—ABL1—medulla oblongata—brain cancer	0.000136	0.0013	CbGeAlD
Dasatinib—FGR—brain—brain cancer	0.000136	0.0013	CbGeAlD
Dasatinib—Tremor—Temozolomide—brain cancer	0.000136	0.0011	CcSEcCtD
Dasatinib—SRC—cerebellum—brain cancer	0.000136	0.0013	CbGeAlD
Dasatinib—Dyspnoea—Hydroxyurea—brain cancer	0.000135	0.0011	CcSEcCtD
Dasatinib—Somnolence—Hydroxyurea—brain cancer	0.000135	0.00109	CcSEcCtD
Dasatinib—Ill-defined disorder—Temozolomide—brain cancer	0.000135	0.00109	CcSEcCtD
Dasatinib—Anaemia—Temozolomide—brain cancer	0.000134	0.00109	CcSEcCtD
Dasatinib—Diarrhoea—Procarbazine—brain cancer	0.000134	0.00109	CcSEcCtD
Dasatinib—Dyspepsia—Hydroxyurea—brain cancer	0.000133	0.00108	CcSEcCtD
Dasatinib—Decreased appetite—Hydroxyurea—brain cancer	0.000132	0.00107	CcSEcCtD
Dasatinib—Urinary tract disorder—Etoposide—brain cancer	0.000132	0.00107	CcSEcCtD
Dasatinib—FMO3—brain—brain cancer	0.000132	0.00126	CbGeAlD
Dasatinib—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000131	0.00106	CcSEcCtD
Dasatinib—Malaise—Temozolomide—brain cancer	0.000131	0.00106	CcSEcCtD
Dasatinib—Urethral disorder—Etoposide—brain cancer	0.000131	0.00106	CcSEcCtD
Dasatinib—Fatigue—Hydroxyurea—brain cancer	0.000131	0.00106	CcSEcCtD
Dasatinib—Vertigo—Temozolomide—brain cancer	0.00013	0.00106	CcSEcCtD
Dasatinib—Convulsion—Carmustine—brain cancer	0.00013	0.00106	CcSEcCtD
Dasatinib—EPHB4—brain—brain cancer	0.00013	0.00124	CbGeAlD
Dasatinib—Hypertension—Carmustine—brain cancer	0.00013	0.00105	CcSEcCtD
Dasatinib—Pain—Hydroxyurea—brain cancer	0.00013	0.00105	CcSEcCtD
Dasatinib—Constipation—Hydroxyurea—brain cancer	0.00013	0.00105	CcSEcCtD
Dasatinib—Dizziness—Procarbazine—brain cancer	0.000129	0.00105	CcSEcCtD
Dasatinib—JAK2—brain—brain cancer	0.000129	0.00123	CbGeAlD
Dasatinib—Palpitations—Temozolomide—brain cancer	0.000128	0.00104	CcSEcCtD
Dasatinib—MAP2K5—central nervous system—brain cancer	0.000128	0.00122	CbGeAlD
Dasatinib—Chest pain—Carmustine—brain cancer	0.000128	0.00104	CcSEcCtD
Dasatinib—Myalgia—Carmustine—brain cancer	0.000128	0.00104	CcSEcCtD
Dasatinib—Anxiety—Carmustine—brain cancer	0.000127	0.00103	CcSEcCtD
Dasatinib—EPHA2—brain—brain cancer	0.000127	0.00122	CbGeAlD
Dasatinib—FYN—brain—brain cancer	0.000127	0.00121	CbGeAlD
Dasatinib—Cough—Temozolomide—brain cancer	0.000127	0.00103	CcSEcCtD
Dasatinib—Erythema multiforme—Etoposide—brain cancer	0.000126	0.00102	CcSEcCtD
Dasatinib—KIT—endocrine gland—brain cancer	0.000126	0.0012	CbGeAlD
Dasatinib—Convulsion—Temozolomide—brain cancer	0.000126	0.00102	CcSEcCtD
Dasatinib—Hypertension—Temozolomide—brain cancer	0.000125	0.00102	CcSEcCtD
Dasatinib—MAP2K5—cerebellum—brain cancer	0.000125	0.00119	CbGeAlD
Dasatinib—Feeling abnormal—Hydroxyurea—brain cancer	0.000125	0.00101	CcSEcCtD
Dasatinib—CSF1R—central nervous system—brain cancer	0.000125	0.00119	CbGeAlD
Dasatinib—Eye disorder—Etoposide—brain cancer	0.000125	0.00101	CcSEcCtD
Dasatinib—ABL1—midbrain—brain cancer	0.000125	0.00119	CbGeAlD
Dasatinib—Vomiting—Procarbazine—brain cancer	0.000125	0.00101	CcSEcCtD
Dasatinib—MAP4K5—brain—brain cancer	0.000124	0.00119	CbGeAlD
Dasatinib—MAP3K3—brain—brain cancer	0.000124	0.00119	CbGeAlD
Dasatinib—KIT—head—brain cancer	0.000124	0.00118	CbGeAlD
Dasatinib—Cardiac disorder—Etoposide—brain cancer	0.000124	0.001	CcSEcCtD
Dasatinib—Flushing—Etoposide—brain cancer	0.000124	0.001	CcSEcCtD
Dasatinib—Confusional state—Carmustine—brain cancer	0.000124	0.001	CcSEcCtD
Dasatinib—Myalgia—Temozolomide—brain cancer	0.000124	0.001	CcSEcCtD
Dasatinib—Arthralgia—Temozolomide—brain cancer	0.000124	0.001	CcSEcCtD
Dasatinib—Rash—Procarbazine—brain cancer	0.000123	0.001	CcSEcCtD
Dasatinib—Dermatitis—Procarbazine—brain cancer	0.000123	0.001	CcSEcCtD
Dasatinib—Anxiety—Temozolomide—brain cancer	0.000123	0.000999	CcSEcCtD
Dasatinib—PDGFRB—endocrine gland—brain cancer	0.000123	0.00117	CbGeAlD
Dasatinib—Headache—Procarbazine—brain cancer	0.000123	0.000996	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000123	0.000996	CcSEcCtD
Dasatinib—CYP1B1—gonad—brain cancer	0.000123	0.00117	CbGeAlD
Dasatinib—Oedema—Carmustine—brain cancer	0.000123	0.000995	CcSEcCtD
Dasatinib—Discomfort—Temozolomide—brain cancer	0.000122	0.000991	CcSEcCtD
Dasatinib—CSF1R—cerebellum—brain cancer	0.000122	0.00116	CbGeAlD
Dasatinib—Infection—Carmustine—brain cancer	0.000122	0.000988	CcSEcCtD
Dasatinib—ABL1—spinal cord—brain cancer	0.000122	0.00116	CbGeAlD
Dasatinib—PDGFRB—head—brain cancer	0.000121	0.00116	CbGeAlD
Dasatinib—Angiopathy—Etoposide—brain cancer	0.000121	0.000982	CcSEcCtD
Dasatinib—Immune system disorder—Etoposide—brain cancer	0.00012	0.000978	CcSEcCtD
Dasatinib—Mediastinal disorder—Etoposide—brain cancer	0.00012	0.000976	CcSEcCtD
Dasatinib—Thrombocytopenia—Carmustine—brain cancer	0.00012	0.000974	CcSEcCtD
Dasatinib—Body temperature increased—Hydroxyurea—brain cancer	0.00012	0.000973	CcSEcCtD
Dasatinib—Chills—Etoposide—brain cancer	0.00012	0.000972	CcSEcCtD
Dasatinib—CYP1B1—pituitary gland—brain cancer	0.00012	0.00114	CbGeAlD
Dasatinib—Tachycardia—Carmustine—brain cancer	0.00012	0.000971	CcSEcCtD
Dasatinib—Confusional state—Temozolomide—brain cancer	0.000119	0.000969	CcSEcCtD
Dasatinib—EPHB6—brain—brain cancer	0.000119	0.00113	CbGeAlD
Dasatinib—Oedema—Temozolomide—brain cancer	0.000118	0.000961	CcSEcCtD
Dasatinib—Alopecia—Etoposide—brain cancer	0.000118	0.000957	CcSEcCtD
Dasatinib—Infection—Temozolomide—brain cancer	0.000118	0.000955	CcSEcCtD
Dasatinib—Anorexia—Carmustine—brain cancer	0.000117	0.000948	CcSEcCtD
Dasatinib—Nausea—Procarbazine—brain cancer	0.000116	0.000944	CcSEcCtD
Dasatinib—Nervous system disorder—Temozolomide—brain cancer	0.000116	0.000943	CcSEcCtD
Dasatinib—Thrombocytopenia—Temozolomide—brain cancer	0.000116	0.000941	CcSEcCtD
Dasatinib—Skin disorder—Temozolomide—brain cancer	0.000115	0.000934	CcSEcCtD
Dasatinib—YES1—brain—brain cancer	0.000115	0.00109	CbGeAlD
Dasatinib—Hypotension—Carmustine—brain cancer	0.000114	0.00093	CcSEcCtD
Dasatinib—Hyperhidrosis—Temozolomide—brain cancer	0.000114	0.000929	CcSEcCtD
Dasatinib—Dysgeusia—Etoposide—brain cancer	0.000114	0.000923	CcSEcCtD
Dasatinib—KIT—central nervous system—brain cancer	0.000113	0.00108	CbGeAlD
Dasatinib—Anorexia—Temozolomide—brain cancer	0.000113	0.000916	CcSEcCtD
Dasatinib—PDGFRA—brain—brain cancer	0.000113	0.00107	CbGeAlD
Dasatinib—Hypersensitivity—Hydroxyurea—brain cancer	0.000112	0.000907	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Carmustine—brain cancer	0.000112	0.000906	CcSEcCtD
Dasatinib—Muscle spasms—Etoposide—brain cancer	0.000112	0.000906	CcSEcCtD
Dasatinib—ABCB1—blood vessel—brain cancer	0.000111	0.00106	CbGeAlD
Dasatinib—Insomnia—Carmustine—brain cancer	0.000111	0.0009	CcSEcCtD
Dasatinib—KIT—cerebellum—brain cancer	0.000111	0.00106	CbGeAlD
Dasatinib—PDGFRB—central nervous system—brain cancer	0.000111	0.00106	CbGeAlD
Dasatinib—SRC—brain—brain cancer	0.00011	0.00105	CbGeAlD
Dasatinib—ABL1—endocrine gland—brain cancer	0.000109	0.00104	CbGeAlD
Dasatinib—ABCG2—telencephalon—brain cancer	0.000109	0.00104	CbGeAlD
Dasatinib—Dyspnoea—Carmustine—brain cancer	0.000109	0.000887	CcSEcCtD
Dasatinib—Somnolence—Carmustine—brain cancer	0.000109	0.000884	CcSEcCtD
Dasatinib—Asthenia—Hydroxyurea—brain cancer	0.000109	0.000883	CcSEcCtD
Dasatinib—PDGFRB—cerebellum—brain cancer	0.000108	0.00103	CbGeAlD
Dasatinib—ABL1—head—brain cancer	0.000108	0.00103	CbGeAlD
Dasatinib—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000108	0.000876	CcSEcCtD
Dasatinib—Ill-defined disorder—Etoposide—brain cancer	0.000108	0.000875	CcSEcCtD
Dasatinib—Anaemia—Etoposide—brain cancer	0.000107	0.000871	CcSEcCtD
Dasatinib—Insomnia—Temozolomide—brain cancer	0.000107	0.00087	CcSEcCtD
Dasatinib—Decreased appetite—Carmustine—brain cancer	0.000107	0.000865	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Carmustine—brain cancer	0.000106	0.000859	CcSEcCtD
Dasatinib—Dyspnoea—Temozolomide—brain cancer	0.000106	0.000857	CcSEcCtD
Dasatinib—Somnolence—Temozolomide—brain cancer	0.000105	0.000855	CcSEcCtD
Dasatinib—Pain—Carmustine—brain cancer	0.000105	0.000851	CcSEcCtD
Dasatinib—Constipation—Carmustine—brain cancer	0.000105	0.000851	CcSEcCtD
Dasatinib—Malaise—Etoposide—brain cancer	0.000105	0.00085	CcSEcCtD
Dasatinib—Vertigo—Etoposide—brain cancer	0.000104	0.000847	CcSEcCtD
Dasatinib—Dyspepsia—Temozolomide—brain cancer	0.000104	0.000846	CcSEcCtD
Dasatinib—Diarrhoea—Hydroxyurea—brain cancer	0.000104	0.000842	CcSEcCtD
Dasatinib—Decreased appetite—Temozolomide—brain cancer	0.000103	0.000836	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Temozolomide—brain cancer	0.000102	0.00083	CcSEcCtD
Dasatinib—Fatigue—Temozolomide—brain cancer	0.000102	0.000829	CcSEcCtD
Dasatinib—Loss of consciousness—Etoposide—brain cancer	0.000102	0.000828	CcSEcCtD
Dasatinib—MAP2K5—brain—brain cancer	0.000102	0.000969	CbGeAlD
Dasatinib—Cough—Etoposide—brain cancer	0.000101	0.000823	CcSEcCtD
Dasatinib—Constipation—Temozolomide—brain cancer	0.000101	0.000822	CcSEcCtD
Dasatinib—Pain—Temozolomide—brain cancer	0.000101	0.000822	CcSEcCtD
Dasatinib—Feeling abnormal—Carmustine—brain cancer	0.000101	0.00082	CcSEcCtD
Dasatinib—Convulsion—Etoposide—brain cancer	0.000101	0.000817	CcSEcCtD
Dasatinib—Hypertension—Etoposide—brain cancer	0.0001	0.000814	CcSEcCtD
Dasatinib—Dizziness—Hydroxyurea—brain cancer	0.0001	0.000814	CcSEcCtD
Dasatinib—Gastrointestinal pain—Carmustine—brain cancer	0.0001	0.000813	CcSEcCtD
Dasatinib—CSF1R—brain—brain cancer	9.91e-05	0.000946	CbGeAlD
Dasatinib—Chest pain—Etoposide—brain cancer	9.88e-05	0.000802	CcSEcCtD
Dasatinib—ABL1—central nervous system—brain cancer	9.86e-05	0.000942	CbGeAlD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	9.81e-05	0.000797	CcSEcCtD
Dasatinib—Discomfort—Etoposide—brain cancer	9.76e-05	0.000793	CcSEcCtD
Dasatinib—Feeling abnormal—Temozolomide—brain cancer	9.76e-05	0.000792	CcSEcCtD
Dasatinib—Abdominal pain—Carmustine—brain cancer	9.69e-05	0.000786	CcSEcCtD
Dasatinib—Body temperature increased—Carmustine—brain cancer	9.69e-05	0.000786	CcSEcCtD
Dasatinib—Gastrointestinal pain—Temozolomide—brain cancer	9.68e-05	0.000786	CcSEcCtD
Dasatinib—ABL1—cerebellum—brain cancer	9.64e-05	0.00092	CbGeAlD
Dasatinib—Vomiting—Hydroxyurea—brain cancer	9.64e-05	0.000782	CcSEcCtD
Dasatinib—Rash—Hydroxyurea—brain cancer	9.56e-05	0.000776	CcSEcCtD
Dasatinib—Confusional state—Etoposide—brain cancer	9.55e-05	0.000776	CcSEcCtD
Dasatinib—Dermatitis—Hydroxyurea—brain cancer	9.55e-05	0.000775	CcSEcCtD
Dasatinib—Headache—Hydroxyurea—brain cancer	9.49e-05	0.000771	CcSEcCtD
Dasatinib—Infection—Etoposide—brain cancer	9.41e-05	0.000764	CcSEcCtD
Dasatinib—Urticaria—Temozolomide—brain cancer	9.41e-05	0.000764	CcSEcCtD
Dasatinib—Abdominal pain—Temozolomide—brain cancer	9.36e-05	0.00076	CcSEcCtD
Dasatinib—Body temperature increased—Temozolomide—brain cancer	9.36e-05	0.00076	CcSEcCtD
Dasatinib—Thrombocytopenia—Etoposide—brain cancer	9.28e-05	0.000753	CcSEcCtD
Dasatinib—CYP1B1—endocrine gland—brain cancer	9.27e-05	0.000885	CbGeAlD
Dasatinib—Tachycardia—Etoposide—brain cancer	9.25e-05	0.000751	CcSEcCtD
Dasatinib—Skin disorder—Etoposide—brain cancer	9.2e-05	0.000747	CcSEcCtD
Dasatinib—Hyperhidrosis—Etoposide—brain cancer	9.16e-05	0.000744	CcSEcCtD
Dasatinib—CYP1B1—head—brain cancer	9.15e-05	0.000874	CbGeAlD
Dasatinib—Anorexia—Etoposide—brain cancer	9.03e-05	0.000733	CcSEcCtD
Dasatinib—Hypersensitivity—Carmustine—brain cancer	9.03e-05	0.000733	CcSEcCtD
Dasatinib—Nausea—Hydroxyurea—brain cancer	9e-05	0.000731	CcSEcCtD
Dasatinib—KIT—brain—brain cancer	8.99e-05	0.000859	CbGeAlD
Dasatinib—ABCG2—pituitary gland—brain cancer	8.91e-05	0.000851	CbGeAlD
Dasatinib—Hypotension—Etoposide—brain cancer	8.85e-05	0.000719	CcSEcCtD
Dasatinib—Asthenia—Carmustine—brain cancer	8.79e-05	0.000714	CcSEcCtD
Dasatinib—PDGFRB—brain—brain cancer	8.79e-05	0.000839	CbGeAlD
Dasatinib—Hypersensitivity—Temozolomide—brain cancer	8.72e-05	0.000708	CcSEcCtD
Dasatinib—ABCG2—medulla oblongata—brain cancer	8.6e-05	0.000821	CbGeAlD
Dasatinib—Asthenia—Temozolomide—brain cancer	8.49e-05	0.00069	CcSEcCtD
Dasatinib—Dyspnoea—Etoposide—brain cancer	8.45e-05	0.000686	CcSEcCtD
Dasatinib—Somnolence—Etoposide—brain cancer	8.42e-05	0.000684	CcSEcCtD
Dasatinib—Diarrhoea—Carmustine—brain cancer	8.38e-05	0.000681	CcSEcCtD
Dasatinib—Pruritus—Temozolomide—brain cancer	8.38e-05	0.00068	CcSEcCtD
Dasatinib—CYP1B1—central nervous system—brain cancer	8.35e-05	0.000797	CbGeAlD
Dasatinib—Decreased appetite—Etoposide—brain cancer	8.24e-05	0.000669	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Etoposide—brain cancer	8.18e-05	0.000664	CcSEcCtD
Dasatinib—Fatigue—Etoposide—brain cancer	8.17e-05	0.000663	CcSEcCtD
Dasatinib—CYP1B1—cerebellum—brain cancer	8.16e-05	0.000779	CbGeAlD
Dasatinib—Dizziness—Carmustine—brain cancer	8.1e-05	0.000658	CcSEcCtD
Dasatinib—Constipation—Etoposide—brain cancer	8.1e-05	0.000658	CcSEcCtD
Dasatinib—Pain—Etoposide—brain cancer	8.1e-05	0.000658	CcSEcCtD
Dasatinib—Diarrhoea—Temozolomide—brain cancer	8.1e-05	0.000658	CcSEcCtD
Dasatinib—ABCG2—midbrain—brain cancer	7.86e-05	0.00075	CbGeAlD
Dasatinib—ABL1—brain—brain cancer	7.83e-05	0.000748	CbGeAlD
Dasatinib—Dizziness—Temozolomide—brain cancer	7.83e-05	0.000636	CcSEcCtD
Dasatinib—Feeling abnormal—Etoposide—brain cancer	7.81e-05	0.000634	CcSEcCtD
Dasatinib—Vomiting—Carmustine—brain cancer	7.79e-05	0.000633	CcSEcCtD
Dasatinib—Gastrointestinal pain—Etoposide—brain cancer	7.75e-05	0.000629	CcSEcCtD
Dasatinib—Rash—Carmustine—brain cancer	7.72e-05	0.000627	CcSEcCtD
Dasatinib—Dermatitis—Carmustine—brain cancer	7.72e-05	0.000627	CcSEcCtD
Dasatinib—Headache—Carmustine—brain cancer	7.68e-05	0.000623	CcSEcCtD
Dasatinib—ABCG2—spinal cord—brain cancer	7.67e-05	0.000732	CbGeAlD
Dasatinib—Vomiting—Temozolomide—brain cancer	7.53e-05	0.000611	CcSEcCtD
Dasatinib—Urticaria—Etoposide—brain cancer	7.53e-05	0.000611	CcSEcCtD
Dasatinib—Body temperature increased—Etoposide—brain cancer	7.49e-05	0.000608	CcSEcCtD
Dasatinib—Abdominal pain—Etoposide—brain cancer	7.49e-05	0.000608	CcSEcCtD
Dasatinib—Rash—Temozolomide—brain cancer	7.47e-05	0.000606	CcSEcCtD
Dasatinib—Dermatitis—Temozolomide—brain cancer	7.46e-05	0.000606	CcSEcCtD
Dasatinib—Headache—Temozolomide—brain cancer	7.42e-05	0.000602	CcSEcCtD
Dasatinib—Nausea—Carmustine—brain cancer	7.28e-05	0.000591	CcSEcCtD
Dasatinib—Nausea—Temozolomide—brain cancer	7.03e-05	0.000571	CcSEcCtD
Dasatinib—Hypersensitivity—Etoposide—brain cancer	6.98e-05	0.000567	CcSEcCtD
Dasatinib—Asthenia—Etoposide—brain cancer	6.8e-05	0.000552	CcSEcCtD
Dasatinib—Pruritus—Etoposide—brain cancer	6.7e-05	0.000544	CcSEcCtD
Dasatinib—CYP1A2—endocrine gland—brain cancer	6.64e-05	0.000634	CbGeAlD
Dasatinib—CYP1B1—brain—brain cancer	6.63e-05	0.000633	CbGeAlD
Dasatinib—CYP1A1—endocrine gland—brain cancer	6.55e-05	0.000626	CbGeAlD
Dasatinib—Diarrhoea—Etoposide—brain cancer	6.48e-05	0.000526	CcSEcCtD
Dasatinib—CYP1A1—head—brain cancer	6.47e-05	0.000618	CbGeAlD
Dasatinib—CYP3A5—endocrine gland—brain cancer	6.41e-05	0.000612	CbGeAlD
Dasatinib—Dizziness—Etoposide—brain cancer	6.27e-05	0.000509	CcSEcCtD
Dasatinib—ABCG2—cerebellum—brain cancer	6.08e-05	0.00058	CbGeAlD
Dasatinib—Vomiting—Etoposide—brain cancer	6.02e-05	0.000489	CcSEcCtD
Dasatinib—Rash—Etoposide—brain cancer	5.97e-05	0.000485	CcSEcCtD
Dasatinib—Dermatitis—Etoposide—brain cancer	5.97e-05	0.000485	CcSEcCtD
Dasatinib—Headache—Etoposide—brain cancer	5.94e-05	0.000482	CcSEcCtD
Dasatinib—CYP1A1—central nervous system—brain cancer	5.9e-05	0.000564	CbGeAlD
Dasatinib—Nausea—Etoposide—brain cancer	5.63e-05	0.000457	CcSEcCtD
Dasatinib—ABCB1—telencephalon—brain cancer	5.4e-05	0.000515	CbGeAlD
Dasatinib—ABCG2—brain—brain cancer	4.94e-05	0.000471	CbGeAlD
Dasatinib—CYP3A4—endocrine gland—brain cancer	4.81e-05	0.000459	CbGeAlD
Dasatinib—CYP1A1—brain—brain cancer	4.69e-05	0.000448	CbGeAlD
Dasatinib—ABCB1—gonad—brain cancer	4.5e-05	0.00043	CbGeAlD
Dasatinib—ABCB1—pituitary gland—brain cancer	4.39e-05	0.000419	CbGeAlD
Dasatinib—CYP3A4—central nervous system—brain cancer	4.33e-05	0.000414	CbGeAlD
Dasatinib—ABCB1—medulla oblongata—brain cancer	4.24e-05	0.000405	CbGeAlD
Dasatinib—ABCB1—midbrain—brain cancer	3.88e-05	0.00037	CbGeAlD
Dasatinib—ABCB1—spinal cord—brain cancer	3.78e-05	0.000361	CbGeAlD
Dasatinib—ABCB1—endocrine gland—brain cancer	3.4e-05	0.000325	CbGeAlD
Dasatinib—ABCB1—head—brain cancer	3.36e-05	0.000321	CbGeAlD
Dasatinib—ABCB1—central nervous system—brain cancer	3.07e-05	0.000293	CbGeAlD
Dasatinib—ABCB1—cerebellum—brain cancer	3e-05	0.000286	CbGeAlD
Dasatinib—ABCB1—brain—brain cancer	2.43e-05	0.000232	CbGeAlD
Dasatinib—MAPK14—Immune System—ERBB2—brain cancer	2.5e-06	1.57e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—APC—brain cancer	2.49e-06	1.57e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CG—brain cancer	2.49e-06	1.57e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—ERBB2—brain cancer	2.49e-06	1.57e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IRS2—brain cancer	2.49e-06	1.56e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—RELA—brain cancer	2.49e-06	1.56e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—IDH1—brain cancer	2.48e-06	1.56e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—EGFR—brain cancer	2.47e-06	1.55e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—ERBB2—brain cancer	2.47e-06	1.55e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ENO2—brain cancer	2.46e-06	1.55e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—EGFR—brain cancer	2.45e-06	1.54e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL2—brain cancer	2.45e-06	1.54e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL2—brain cancer	2.45e-06	1.54e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IRS2—brain cancer	2.45e-06	1.54e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL2—brain cancer	2.44e-06	1.54e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HES1—brain cancer	2.44e-06	1.53e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—CTNNB1—brain cancer	2.42e-06	1.52e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—STAT3—brain cancer	2.41e-06	1.52e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TP53—brain cancer	2.4e-06	1.51e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—ERBB2—brain cancer	2.4e-06	1.51e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL2—brain cancer	2.39e-06	1.5e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—CCND1—brain cancer	2.39e-06	1.5e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL2—brain cancer	2.38e-06	1.5e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TP53—brain cancer	2.38e-06	1.5e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—CTNNB1—brain cancer	2.37e-06	1.49e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL2—brain cancer	2.36e-06	1.49e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IRS2—brain cancer	2.36e-06	1.48e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—CTNNB1—brain cancer	2.36e-06	1.48e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL2—brain cancer	2.36e-06	1.48e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IRS2—brain cancer	2.33e-06	1.46e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PDGFRA—brain cancer	2.32e-06	1.46e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—CTNNB1—brain cancer	2.31e-06	1.45e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TP53—brain cancer	2.31e-06	1.45e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—CCND1—brain cancer	2.3e-06	1.45e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—RELA—brain cancer	2.3e-06	1.45e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—CTNNB1—brain cancer	2.3e-06	1.45e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CG—brain cancer	2.29e-06	1.44e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—ERBB2—brain cancer	2.29e-06	1.44e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—STAT3—brain cancer	2.28e-06	1.44e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—CTNNB1—brain cancer	2.28e-06	1.43e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—ERBB2—brain cancer	2.28e-06	1.43e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—EGFR—brain cancer	2.28e-06	1.43e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—VEGFA—brain cancer	2.28e-06	1.43e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—APC—brain cancer	2.28e-06	1.43e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—CTNNB1—brain cancer	2.27e-06	1.43e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL2—brain cancer	2.27e-06	1.43e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SPP1—brain cancer	2.26e-06	1.42e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—STAT3—brain cancer	2.26e-06	1.42e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CG—brain cancer	2.25e-06	1.41e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—APC—brain cancer	2.25e-06	1.41e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL2—brain cancer	2.24e-06	1.41e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—BSG—brain cancer	2.23e-06	1.4e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—STAT3—brain cancer	2.23e-06	1.4e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CG—brain cancer	2.2e-06	1.38e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—APC—brain cancer	2.2e-06	1.38e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—EGFR—brain cancer	2.19e-06	1.38e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CTNNB1—brain cancer	2.19e-06	1.38e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—EGFR—brain cancer	2.19e-06	1.38e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—CTNNB1—brain cancer	2.18e-06	1.37e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—RELA—brain cancer	2.18e-06	1.37e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CG—brain cancer	2.16e-06	1.36e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—APC—brain cancer	2.16e-06	1.36e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—ERBB2—brain cancer	2.16e-06	1.36e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CTNNB1—brain cancer	2.16e-06	1.36e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HES1—brain cancer	2.16e-06	1.36e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—brain cancer	2.13e-06	1.34e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—STAT3—brain cancer	2.11e-06	1.33e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—CTNNB1—brain cancer	2.1e-06	1.32e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—MYC—brain cancer	2.1e-06	1.32e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CG—brain cancer	2.09e-06	1.31e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CG—brain cancer	2.08e-06	1.31e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—APC—brain cancer	2.08e-06	1.31e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—VEGFA—brain cancer	2.08e-06	1.31e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL2—brain cancer	2.07e-06	1.3e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—EGFR—brain cancer	2.07e-06	1.3e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—MYC—brain cancer	2.07e-06	1.3e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—STAT3—brain cancer	2.06e-06	1.3e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—RELA—brain cancer	2.06e-06	1.29e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PDGFRA—brain cancer	2.06e-06	1.29e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—APC—brain cancer	2.06e-06	1.29e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CG—brain cancer	2.06e-06	1.29e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—STAT3—brain cancer	2.06e-06	1.29e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—EGFR—brain cancer	2.05e-06	1.29e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—ERBB2—brain cancer	2.04e-06	1.29e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IRS2—brain cancer	2.04e-06	1.28e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—EGFR—brain cancer	2.02e-06	1.27e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.02e-06	1.27e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CCND1—brain cancer	2.02e-06	1.27e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—STAT3—brain cancer	2.01e-06	1.27e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—VEGFA—brain cancer	2.01e-06	1.26e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—STAT3—brain cancer	2e-06	1.26e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CTNNB1—brain cancer	2e-06	1.26e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—ERBB2—brain cancer	2e-06	1.26e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SPP1—brain cancer	2e-06	1.26e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—CTNNB1—brain cancer	2e-06	1.25e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—STAT3—brain cancer	1.99e-06	1.25e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—STAT3—brain cancer	1.98e-06	1.25e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ENO2—brain cancer	1.96e-06	1.23e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL2—brain cancer	1.96e-06	1.23e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—MYC—brain cancer	1.96e-06	1.23e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—RELA—brain cancer	1.95e-06	1.22e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—ERBB2—brain cancer	1.93e-06	1.22e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—RELA—brain cancer	1.93e-06	1.21e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—IDH1—brain cancer	1.92e-06	1.21e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MYC—brain cancer	1.92e-06	1.21e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—ERBB2—brain cancer	1.92e-06	1.2e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—EGFR—brain cancer	1.92e-06	1.2e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—STAT3—brain cancer	1.91e-06	1.2e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—STAT3—brain cancer	1.9e-06	1.19e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CTNNB1—brain cancer	1.89e-06	1.19e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—STAT3—brain cancer	1.88e-06	1.18e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—EGFR—brain cancer	1.88e-06	1.18e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—EGFR—brain cancer	1.87e-06	1.18e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—EGFR—brain cancer	1.87e-06	1.18e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL2—brain cancer	1.85e-06	1.16e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MYC—brain cancer	1.85e-06	1.16e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—STAT3—brain cancer	1.83e-06	1.15e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—EGFR—brain cancer	1.83e-06	1.15e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—EGFR—brain cancer	1.82e-06	1.15e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—EGFR—brain cancer	1.81e-06	1.14e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CCND1—brain cancer	1.81e-06	1.14e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IRS2—brain cancer	1.81e-06	1.14e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—APC—brain cancer	1.8e-06	1.13e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CG—brain cancer	1.8e-06	1.13e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—EGFR—brain cancer	1.8e-06	1.13e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CTNNB1—brain cancer	1.79e-06	1.12e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—ERBB2—brain cancer	1.77e-06	1.11e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—MYC—brain cancer	1.76e-06	1.11e-05	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—MYC—brain cancer	1.76e-06	1.11e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—VEGFA—brain cancer	1.76e-06	1.11e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—RELA—brain cancer	1.75e-06	1.1e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL2—brain cancer	1.75e-06	1.1e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—CTNNB1—brain cancer	1.75e-06	1.1e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—STAT3—brain cancer	1.75e-06	1.1e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—ERBB2—brain cancer	1.74e-06	1.1e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—STAT3—brain cancer	1.74e-06	1.09e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL2—brain cancer	1.74e-06	1.09e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—EGFR—brain cancer	1.73e-06	1.09e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—EGFR—brain cancer	1.73e-06	1.08e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—brain cancer	1.72e-06	1.08e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—RELA—brain cancer	1.72e-06	1.08e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—EGFR—brain cancer	1.71e-06	1.08e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CCND1—brain cancer	1.71e-06	1.07e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—ERBB2—brain cancer	1.71e-06	1.07e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—MYC—brain cancer	1.7e-06	1.07e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CTNNB1—brain cancer	1.69e-06	1.06e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—RELA—brain cancer	1.69e-06	1.06e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—ERBB2—brain cancer	1.68e-06	1.06e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CTNNB1—brain cancer	1.68e-06	1.05e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—EGFR—brain cancer	1.66e-06	1.05e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—STAT3—brain cancer	1.65e-06	1.04e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—RELA—brain cancer	1.63e-06	1.02e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MYC—brain cancer	1.62e-06	1.02e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—ERBB2—brain cancer	1.62e-06	1.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—MYC—brain cancer	1.62e-06	1.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—RELA—brain cancer	1.61e-06	1.01e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—ERBB2—brain cancer	1.6e-06	1e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—APC—brain cancer	1.59e-06	1e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CG—brain cancer	1.59e-06	1e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EGFR—brain cancer	1.59e-06	9.98e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—EGFR—brain cancer	1.58e-06	9.94e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL2—brain cancer	1.58e-06	9.93e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—VEGFA—brain cancer	1.57e-06	9.9e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—brain cancer	1.57e-06	9.9e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—STAT3—brain cancer	1.56e-06	9.8e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—CTNNB1—brain cancer	1.55e-06	9.73e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL2—brain cancer	1.55e-06	9.73e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CCND1—brain cancer	1.54e-06	9.68e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CTNNB1—brain cancer	1.53e-06	9.59e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—STAT3—brain cancer	1.52e-06	9.58e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL2—brain cancer	1.52e-06	9.58e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—brain cancer	1.52e-06	9.54e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ENO2—brain cancer	1.52e-06	9.53e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CCND1—brain cancer	1.51e-06	9.48e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—EGFR—brain cancer	1.5e-06	9.43e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CG—brain cancer	1.5e-06	9.4e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CTNNB1—brain cancer	1.49e-06	9.39e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—VEGFA—brain cancer	1.49e-06	9.37e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCND1—brain cancer	1.48e-06	9.33e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—STAT3—brain cancer	1.48e-06	9.28e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CTNNB1—brain cancer	1.47e-06	9.24e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL2—brain cancer	1.47e-06	9.22e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—STAT3—brain cancer	1.46e-06	9.19e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MYC—brain cancer	1.45e-06	9.11e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL2—brain cancer	1.45e-06	9.1e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCND1—brain cancer	1.43e-06	8.99e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—brain cancer	1.42e-06	8.91e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MYC—brain cancer	1.42e-06	8.9e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CTNNB1—brain cancer	1.42e-06	8.9e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CG—brain cancer	1.41e-06	8.88e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCND1—brain cancer	1.41e-06	8.87e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—RELA—brain cancer	1.41e-06	8.85e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ERBB2—brain cancer	1.4e-06	8.8e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CTNNB1—brain cancer	1.4e-06	8.79e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—brain cancer	1.38e-06	8.71e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—brain cancer	1.37e-06	8.62e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—STAT3—brain cancer	1.35e-06	8.48e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—brain cancer	1.34e-06	8.44e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—brain cancer	1.34e-06	8.43e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—brain cancer	1.33e-06	8.38e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STAT3—brain cancer	1.33e-06	8.36e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—brain cancer	1.33e-06	8.35e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—brain cancer	1.31e-06	8.27e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—brain cancer	1.3e-06	8.18e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—brain cancer	1.29e-06	8.14e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—brain cancer	1.28e-06	8.06e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—brain cancer	1.27e-06	7.97e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—brain cancer	1.25e-06	7.88e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RELA—brain cancer	1.25e-06	7.84e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—brain cancer	1.25e-06	7.84e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB2—brain cancer	1.24e-06	7.79e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—brain cancer	1.24e-06	7.77e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—brain cancer	1.24e-06	7.77e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—brain cancer	1.23e-06	7.76e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—brain cancer	1.23e-06	7.74e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—brain cancer	1.23e-06	7.71e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CTNNB1—brain cancer	1.22e-06	7.7e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—brain cancer	1.22e-06	7.66e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—brain cancer	1.21e-06	7.61e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—brain cancer	1.21e-06	7.6e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—brain cancer	1.19e-06	7.49e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—brain cancer	1.19e-06	7.48e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—brain cancer	1.18e-06	7.44e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—brain cancer	1.16e-06	7.32e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—brain cancer	1.15e-06	7.21e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—brain cancer	1.13e-06	7.12e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CG—brain cancer	1.13e-06	7.1e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—brain cancer	1.13e-06	7.08e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—brain cancer	1.12e-06	7.06e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—brain cancer	1.12e-06	7.05e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—brain cancer	1.11e-06	6.96e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—brain cancer	1.09e-06	6.88e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CTNNB1—brain cancer	1.08e-06	6.81e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—brain cancer	1.08e-06	6.78e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—brain cancer	1.07e-06	6.71e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—brain cancer	1.01e-06	6.38e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—brain cancer	9.93e-07	6.25e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—brain cancer	9.91e-07	6.23e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—brain cancer	9.78e-07	6.15e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—brain cancer	9.7e-07	6.1e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—brain cancer	9.54e-07	6e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—brain cancer	9.44e-07	5.94e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—brain cancer	9.42e-07	5.92e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—brain cancer	9.3e-07	5.84e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CG—brain cancer	9.01e-07	5.66e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—brain cancer	8.78e-07	5.52e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—brain cancer	8.58e-07	5.4e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—brain cancer	8.14e-07	5.12e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—brain cancer	7.21e-07	4.53e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CG—brain cancer	6.95e-07	4.37e-06	CbGpPWpGaD
